AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9619746 — intervention group
Group type: COMPARATOR
Intervention: 5FU alone
Number of subjects: 205
Study 10155207 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching as a surrogate for randomization
Number of subjects: 0
Study 2789926 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 24924 2 mg
Number of subjects: 20
Study 2789926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2789926 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 24924 1 mg
Number of subjects: 20
Study 2789926 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 20
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine with monoamine oxidase inhibitors
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline with monoamine oxidase inhibitors
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline with monoamine oxidase inhibitors
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline with monoamine oxidase inhibitors
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine with imipramine
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline with imipramine
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline with imipramine
Number of subjects: 0
Study 4685619 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline with imipramine
Number of subjects: 0
Study 4685619 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline and adrenaline in local anaesthetics
Number of subjects: 0
Study 4685619 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline inhalation by bronchial asthmatics
Number of subjects: 0
Study 29037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetic foot
Number of subjects: 385
Study 29037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-vascular diseases
Number of subjects: 385
Study 29037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye complication
Number of subjects: 385
Study 29037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile dysfunction
Number of subjects: 385
Study 29037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of depression
Number of subjects: 385
Study 29037887 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 385
Study 29037887 — intervention group
Group type: COMPARATOR
Intervention: Gender
Number of subjects: 385
Study 29037887 — intervention group
Group type: COMPARATOR
Intervention: Duration of diabetes
Number of subjects: 385
Study 29037887 — intervention group
Group type: COMPARATOR
Intervention: HbA1c levels
Number of subjects: 385
Study 26111971 — intervention group
Group type: COMPARATOR
Intervention: Braun continuous peripheral nerve block catheter set (n=30)
Number of subjects: 60
Study 26111971 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel needle‐over‐cannula (n=30)
Number of subjects: 60
Study 23906654 — intervention group
Group type: COMPARATOR
Intervention: Complete decongestive physiotherapy (CDP) for 4 days
Number of subjects: 129
Study 23906654 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete decongestive physiotherapy (CDP) for 11 days
Number of subjects: 129
Study 20299408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (fentanyl ITS)
Number of subjects: 0
Study 20299408 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous (IV) patient-controlled analgesia (PCA)
Number of subjects: 0
Study 18427444 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 0
Study 18427444 — intervention group
Group type: COMPARATOR
Intervention: Open procedures
Number of subjects: 0
Study 16095600 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-complement red wine (RW)
Number of subjects: 45
Study 16095600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholised red wine (DRW)
Number of subjects: 45
Study 16095600 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 45
Study 12696399 — intervention group
Group type: COMPARATOR
Intervention: WHO/ORS (311 mOsml/L)
Number of subjects: 140
Study 12696399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolarity solution (245 mOsm/L)
Number of subjects: 140
Study 10215673 — intervention group
Group type: EXPERIMENTAL
Intervention: levo-alpha-acetylmethadol (LAAM) 60 mg/70 kg p.o.
Number of subjects: 5
Study 10215673 — intervention group
Group type: EXPERIMENTAL
Intervention: methadone 60 mg/70 kg p.o.
Number of subjects: 5
Study 10215673 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 1.0 mg/70 kg i.m. after LAAM
Number of subjects: 5
Study 10215673 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study 8965941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations regarding fibers
Number of subjects: 73
Study 8965941 — intervention group
Group type: COMPARATOR
Intervention: Dietary fibers intake
Number of subjects: 73
Study 8965941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and laxative treatment, combined with biofeedback training
Number of subjects: 73
Study 1829515 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 micrograms) in Group A, 4 doses at 0, 1, 2, and 12 months.
Number of subjects: 110
Study 1829515 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (10 micrograms) in Group B, 4 doses at 0, 1, 2, and 12 months.
Number of subjects: 110
Study 1829515 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 micrograms) in Group C, 3 doses at 0, 1, and 6 months.
Number of subjects: 110
Study 1829515 — intervention group
Group type: COMPARATOR
Intervention: All groups received a dose (145 IU) of hepatitis B immunoglobulin soon after birth.
Number of subjects: 110
Study 6624186 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg orally)
Number of subjects: 24
Study 6624186 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg orally)
Number of subjects: 24
Study 31815085 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular non-absorbable skin sutures (SS)
Number of subjects: 369
Study 31815085 — intervention group
Group type: COMPARATOR
Intervention: Skin staples (SC)
Number of subjects: 369
Study 29299592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, 5% cream (n=468)
Number of subjects: 932
Study 29299592 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream (n=464)
Number of subjects: 932
Study 27100440 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (OL-HDF)
Number of subjects: 20
Study 27100440 — intervention group
Group type: COMPARATOR
Intervention: Conventional Hemodialysis (HD)
Number of subjects: 20
Study 24417745 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 165
Study 22234404 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR)
Number of subjects: 453
Study 22234404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PHR)
Number of subjects: 453
Study 18680634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-stable fat emulsion
Number of subjects: 11
Study 18680634 — intervention group
Group type: COMPARATOR
Intervention: Acid-unstable fat emulsion
Number of subjects: 11
Study 17113353 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan and 30 mg morphine combination (MS/DM)
Number of subjects: 22
Study 17113353 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine (MS)
Number of subjects: 22
Study 17113353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15638877 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 20
Study 15638877 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic controls
Number of subjects: 20
Study 11828809 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective treatments for psychiatric sequelae of trauma
Number of subjects: 0
Study 10192638 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanesulfonyl fluoride (MSF) at doses of up to 0.18 mg/kg given three times per week for 16 weeks
Number of subjects: 15
Study 10192638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7754477 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide SR 6 mg/day
Number of subjects: 30
Study 7754477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2271089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for 1 month)
Number of subjects: 31
Study 2271089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g coconut oil)
Number of subjects: 31
Study 2271089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (EPA+ re-group)
Number of subjects: 31
Study 2271089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (EPA- re-group)
Number of subjects: 31
Study 7282650 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitation condition focusing on conversational interaction
Number of subjects: 49
Study 7282650 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitation condition with cognitively challenging games and conversation
Number of subjects: 49
Study 7282650 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 49
Study 29364040 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Trapezius Dry Needling (UT DN)
Number of subjects: 40
Study 29364040 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraspinatus Dry Needling (ISP DN)
Number of subjects: 40
Study 29122618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (one-hour session, five sessions/week during chemoradiotherapy)
Number of subjects: 114
Study 29122618 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 114
Study 29122618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 114
Study 26606263 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. paracetamol (1 g paracetamol + 3.91 g mannitol in 100 ml)
Number of subjects: 24
Study 26606263 — intervention group
Group type: COMPARATOR
Intervention: i.v. normal saline (100 ml)
Number of subjects: 24
Study 26606263 — intervention group
Group type: COMPARATOR
Intervention: i.v. mannitol (3.91 g mannitol in 100 ml)
Number of subjects: 24
Study 24647740 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical carotid sinus stimulator ON
Number of subjects: 16
Study 24647740 — intervention group
Group type: COMPARATOR
Intervention: Electrical carotid sinus stimulator OFF
Number of subjects: 16
Study 21874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 120
Study 21874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Drains designed for re‐transfusion of shed blood
Number of subjects: 120
Study 21874574 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 120
Study 20585236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglytone 6211 suture material
Number of subjects: 0
Study 20585236 — intervention group
Group type: COMPARATOR
Intervention: Poliglecaprone 25 suture material
Number of subjects: 0
Study 17427535 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC + ABZ
Number of subjects: 280
Study 17427535 — intervention group
Group type: COMPARATOR
Intervention: DEC
Number of subjects: 280
Study 17427535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 280
Study 15105059 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg twice, 12 hours apart
Number of subjects: 7
Study 15105059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF) 10 mg, single dose
Number of subjects: 7
Study 12238831 — intervention group
Group type: EXPERIMENTAL
Intervention: EndothelinA blocker (BQ‐123, 260 nmoL/min for up to 30 minutes)
Number of subjects: 30
Study 12238831 — intervention group
Group type: EXPERIMENTAL
Intervention: EndothelinA blocker (BQ‐123) and endothelinB blocker (BQ‐788, 260 and 250 nmol/min, respectively, for up to 30 minutes)
Number of subjects: 30
Study 12238831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endothelin blockers)
Number of subjects: 30
Study 9439491 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b and ribavirin (1000 or 1200 mg per day)
Number of subjects: 100
Study 9439491 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b and ribavirin
Number of subjects: 100
Study 9439491 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b and placebo
Number of subjects: 100
Study 7808647 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 40
Study 7808647 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 7808647 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 40
Study 7808647 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2483444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg t.i.d.
Number of subjects: 10
Study 2483444 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg o.d.
Number of subjects: 10
Study 2483444 — intervention group
Group type: COMPARATOR
Intervention: Washout period
Number of subjects: 10
Study 1067530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCL
Number of subjects: 0
Study 1067530 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study 31690170 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREGIVERSPRO-MMD platform
Number of subjects: 74
Study 30831303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus only
Number of subjects: 106
Study 30831303 — intervention group
Group type: COMPARATOR
Intervention: Dorsal and lateral decubitus
Number of subjects: 106
Study 27813052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg 3 times a day, n=20)
Number of subjects: 40
Study 27813052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 25306290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent walking for 30 minutes every 30 minutes for 120 minutes
Number of subjects: 13
Study 25306290 — intervention group
Group type: COMPARATOR
Intervention: Control (no walking)
Number of subjects: 13
Study 24008977 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (0.05 mg/kg bolus followed by 0.05 mg/kg/h for 6 h)
Number of subjects: 80
Study 24008977 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 80
Study 21771256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous LPS (2 ng kg(‐1) of actual body weight)
Number of subjects: 8
Study 21771256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19800820 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 1106
Study 19800820 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1106
Study 16982264 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow inferior alveolar nerve block (IANB) (60 seconds)
Number of subjects: 38
Study 16982264 — intervention group
Group type: COMPARATOR
Intervention: Rapid inferior alveolar nerve block (IANB) (15 seconds)
Number of subjects: 38
Study 15148541 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 23
Study 15148541 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 23
Study 15148541 — intervention group
Group type: COMPARATOR
Intervention: Untreated (baseline)
Number of subjects: 23
Study 17344494 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-nut diet
Number of subjects: 42
Study 17344494 — intervention group
Group type: COMPARATOR
Intervention: Soy-protein diet
Number of subjects: 42
Study 17344494 — intervention group
Group type: COMPARATOR
Intervention: Control diet (DASH)
Number of subjects: 42
Study 10364087 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin therapy (60 mg daily)
Number of subjects: 28
Study 10364087 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (450 IU daily)
Number of subjects: 28
Study 10364087 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 28
Study 8645434 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (performed twice weekly for 6 months at 70% of one repetition maximum)
Number of subjects: 31
Study 8645434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 31
Study 8645434 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 31
Study 1992319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily in the first phase, 200 mg daily in the second phase)
Number of subjects: 61
Study 1992319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 1992319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 61
Study 6416018 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 78
Study 6416018 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin
Number of subjects: 78
Study 6416018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study 31521192 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy after initial treatment with TNF-alpha inhibitor and methotrexate
Number of subjects: 50
Study 31521192 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo and methotrexate
Number of subjects: 50
Study 29266760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to CONSORT guidelines
Number of subjects: 119
Study 29266760 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of random allocation and blinding
Number of subjects: 119
Study 29071949 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of Zusanli (ST 36) and Neiguan (PC 6) for 30 min, once daily for 5 days
Number of subjects: 60
Study 29071949 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 60
Study 25175124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ultra-high dose methylcobalamin (MeCbl), 25 mg/day for 10 days followed by monthly 25 mg for 5 months
Number of subjects: 14
Study 25175124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ultra-high dose methylcobalamin (MeCbl)
Number of subjects: 14
Study 21967833 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg) during t-PA infusion
Number of subjects: 40
Study 21967833 — intervention group
Group type: COMPARATOR
Intervention: Non-Edaravone (no edaravone during t-PA infusion)
Number of subjects: 40
Study 19563329 — intervention group
Group type: EXPERIMENTAL
Intervention: ABB+PRP
Number of subjects: 87
Study 19563329 — intervention group
Group type: COMPARATOR
Intervention: ABB
Number of subjects: 87
Study 17610451 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current application for 20 minutes
Number of subjects: 34
Study 17610451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation for 20 minutes
Number of subjects: 34
Study 17610451 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the study)
Number of subjects: 34
Study 14988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 30
Study 12052282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid disorder therapy (specific treatment for lipid disorder)
Number of subjects: 0
Study 12052282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid disorder therapy (for primary prevention of heart disease)
Number of subjects: 0
Study 12052282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid treatment trials focused on stroke risk reduction
Number of subjects: 0
Study 9671997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser therapy
Number of subjects: 50
Study 9671997 — intervention group
Group type: COMPARATOR
Intervention: Control group (H2O2 rinse)
Number of subjects: 50
Study 7924322 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only contraceptives (pill, DMPA, NET-EN, NORPLANT implants)
Number of subjects: 2466
Study 7924322 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal methods (IUD, barrier methods, sterilization)
Number of subjects: 2466
Study 2810536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intravenously every 6 hours for nine doses)
Number of subjects: 47
Study 2810536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 gm intravenously every 6 hours for nine doses)
Number of subjects: 47
Study 2810536 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 30266633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective monthly falls diaries
Number of subjects: 9803
Study 30266633 — intervention group
Group type: COMPARATOR
Intervention: Retrospective postal questionnaires
Number of subjects: 9803
Study 28645473 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with non-DHP CCBs
Number of subjects: 1308
Study 28645473 — intervention group
Group type: COMPARATOR
Intervention: Warfarin with non-DHP CCBs
Number of subjects: 1308
Study 28645473 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1308
Study 28645473 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1308
Study 24595903 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 714
Study 24595903 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 714
Study 22995326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FMT) 3g, 2 doses separated by 72 hours
Number of subjects: 118
Study 22995326 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250mg every 12 hours for 3 days
Number of subjects: 118
Study 21447587 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block for at least three postoperative days
Number of subjects: 503